DNA synthesis pathway enzymes

DNA synthesis pathway enzymes represent a collective group of proteins required for the de novo synthesis of deoxyribonucleotides and the subsequent assembly of these building blocks into DNA polymers [NCBI: Molecular Biology of the Cell]. This category includes key metabolic enzymes like dihydrofolate reductase (DHFR) and thymidylate synthase (TS), which provide the necessary precursors for DNA construction, as well as the core replication apparatus consisting of DNA polymerases, helicases, and topoisomerases [PubMed: PMID 28651611]. These enzymes are fundamental to cell division and the maintenance of genomic integrity across all domains of life. In clinical practice, they are among the most heavily exploited therapeutic targets, particularly in oncology where antimetabolites like 5-fluorouracil and methotrexate are used to starve rapidly dividing cancer cells of DNA precursors [StatPearls: Cancer Chemotherapy]. Additionally, many antimicrobial and antiviral therapies, such as acyclovir and fluoroquinolones, achieve selectivity by targeting pathogen-specific variants of these enzymes [StatPearls: Acyclovir]. However, the high degree of conservation in these pathways often leads to significant off-target effects in human tissues with high turnover rates, such as the hematopoietic system and the gut lining [NCBI: Adverse Effects of Cytotoxic Drugs].

Other names

DNA replication enzymesNucleotide synthesis enzymesDNA metabolic enzymesDNA replication machinery

Inhibition of nucleotide biosynthesis (antimetabolites), competitive inhibition of DNA polymerases, induction of DNA chain termination, and stabilization of DNA-enzyme cleavage complexes [StatPearls: Cancer Chemotherapy].